Ionis Pharmaceuticals Earns $5 Million Milestone Payment
News Dec 29, 2015
Ionis Pharmaceuticals, Inc. has announced that it has earned a $5 million milestone payment from Biogen associated with the validation of an undisclosed target to treat patients with an undisclosed neurological disorder.
Ionis and Biogen have a broad strategic collaboration to develop drugs to treat patients with neurological disorders. For this newest target, Ionis will continue to evaluate the target with the goal of advancing this program into development.
"Our strategic collaboration with Biogen is very successful. Our most advanced program, nusinersen, is currently in Phase 3 clinical studies, and we have a number of other drugs in development. We benefit tremendously from the expertise Biogen brings to our partnered programs. We also benefit financially as these programs advance. Across our four collaborations, we have generated more than $350 million from Biogen as our programs have advanced," said B. Lynne Parshall, chief operating officer at Ionis. "As we enter 2016, we expect to continue to expand our collaboration with Biogen as we identify new targets and move new antisense drugs into development."
PhoreMost and Plexxikon Collaborate to Identify Novel Drug TargetsNews
PhoreMost, the UK-based biopharmaceutical company dedicated to drugging ‘undruggable’ disease targets, today announced it has signed a collaborative agreement with Plexxikon Inc., the small molecule structure-guided R&D centre of Daiichi Sankyo.READ MORE
Anti-Malaria Drugs Delivered With CaffeineNews
Many drug delivery systems, such as capsules and tablets, can be difficult to swallow, especially for children. Making delivery systems out of polymer gels is an attractive option, but usually requires hazardous levels of heavy metals to be used. Now, scientists have found a way to build these gels from caffeine molecules.READ MORE
Lonza Opens World’s Largest Dedicated Cell-and-Gene-Therapy Manufacturing Facility in TexasNews
First-of-its-kind, state-of-the-art manufacturing facility with capacity to produce treatment for thousands of patients suffering from rare genetic disorders or life-threatening diseases.READ MORE